Mutational profile of the CAV-1 gene in breast cancer cases in the ethnic Kashmiri population

Asian Pacific Journal of Cancer Prevention

Volumn 11, Issue 4, 2010, Pages 1099-1105

  Syeed, Nidda ^a,b   Husain, Syed Akhtar ^b   Abdullah, Safiya ^a   Syed Sameer, A ^a   Chowdri, Nissar A ^a   Nanda, Mahoor S ^a   Siddiqi, Mushtaq A ^a  

^a SHER I KASHMIR INSTITUTE OF MEDICAL SCIENCES   (India)

^b JAMIA MILLIA ISLAMIA CENTRAL UNIVERSITY   (India)

Author keywords

AS PCR; Breast cancer; Cav 1; Kashmir; Mutation; PCR SSCP

Indexed keywords

EID: 78650684121     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (55)

1. Arlt MF, Casper AM, Glover TW (2003). Common fragile sites. Cytogenet Genome Res, 100, 92-100.
2. Bagnoli M, Tomassetti A, Figini M, et al (2000). Downmodulation of caveolin-1 expression in human ovarian carcinoma is directly related to alpha-folate receptor overexpression. Oncogene, 19, 4754-63.
3. Bender FC, Reymond MA, Bron C, et al (2000). Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res, 60, 5870-8.
4. Charafe-Jauffret E, Ginestier C, Monville F, et al (2005). Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene, 25, 2273-84.
5. Chen ST, Lin SY, Yeh KT, et al (2004). Mutational, epigenetic, and expressional analyses of caveolin-1gene in breast cancers. Int J Mol Med, 14, 577-82.
6. Cohen AW, Hnasko R, Schubert W, et al (2004). Role of caveolae and caveolins in health and disease. Physiol Rev, 84, 1341-79.
7. Couet J, Sargiacomo M, Lisanti MP (1997). Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J Biol Chem, 272, 30429-38.
8. Cui J, Rohr LR, Swanson G, et al (2001). Hypermethylation of the caveolin-1 gene promoter in prostate cancer. Prostate, 46, 249-56.
9. Engelman JA, Chu C, Lin A, et al (1998). Caveolin-mediated regulation of signaling along the p42/44 MAP kinase cascade in vivo. A role for the caveolin-scaffolding domain. FEBS Lett, 428, 205-11
10. Engelman JA, Lee RJ, Karnezis A, et al (1998). Reciprocal regulation of Neu tyrosine kinase activity and caveolin-1 protein expression in vitro and in vivo. Implications for human breast cancer. J Biol Chem, 273, 20448-55.
11. Engelman JA, Wykoff CC, Yasuhara S, et al (1997). Recombinant expression of caveolin-1 in oncogenically transformed cells abrogates anchorage-independent growth. J Biol Chem, 272, 16374-81.
12. Engelman JA, Zhang XL, Lisanti MP (1998). Genes encoding human caveolin-1 and -2 are co-localized to the D7S522 locus (7q31.1), a known fragile site (FRA7G) that is frequently deleted in human cancers. FEBS Lett, 436, 403-10.
13. Engelman JA, Zhang XL, Lisanti MP (1999). Sequence and detailed organization of the human caveolin-1and -2 genes located near the D7S522 locus (7q31.1).Methylation of a CpGisland in the 5' promoter region of the caveolin-1 gene in human breast cancer cell lines. FEBS Lett, 448, 221-30.
14. Galbiati F, Volonte D, Engelman JA, et al (1998). Targeted downregulation of caveolin-1 is sufficient to drive cell transformation and hyperactivate the p42/44 MAP kinase cascade. EMBO J, 17, 6633-48.
15. Gasser S, Raulet D (2006). The DNA damage response, immunity and cancer. Semin Cancer Biol, 16, 344-7.
16. Glenney, J R, Jr. Tyrosine phosphorylation of a 22-kDa protein is correlated with transformation by Rous sarcoma virus. J. Biol. Chem. 264, 20163-6 (1989).
17. Glenney JR Jr, Zokas L (1989). Novel tyrosine kinase substrates from Rous sarcoma virus-transformed cells are present in the membrane skeleton. J Cell Biol, 108, 2401-8.
18. Han SE, Park KH, Lee G, et al (2004). Mutation and aberrant expression of Caveolin-1 in human oral squamous cell carcinomas and oral cancer cell lines. Int J Oncol, 24, 435-40.
19. Han SY, Druck T, Huebner K (2003). Candidate tumor suppressor genes at FRA7G are coamplified with MET and do not suppress malignancy in a gastric cancer. Genomics, 81, 105-7.
20. Hanahan D, Weinberg RA (2000). The hallmarks of cancer. Cell, 100, 57-70.
21. Hayashi K, Matsuda S, Machida K, et al (2001). Invasion activating caveolin-1mutation in human scirrhous breast cancers. Cancer Res, 61, 2361-4.
22. Hnasko R, Lisanti MP (2003). The biology of caveolae: lessons from caveolin knockout mice and implications for human disease. Mol Interv, 3, 445-64.
23. Huang H, Reed CP, Mordi A, et al (1999). Frequent deletions within FRA7G at 7q31.2 in invasive epithelial ovarian cancer. Genes Chromosomes Cancer, 24, 48-55.
24. Hulit J, Bash T, Fu M, et al (2000). The cyclin D1 gene is transcriptionally repressed by caveolin-1. J Biol Chem, 275, 21203-9.
25. Hurlstone AF, Reid G, Reeves JR, et al (1999). Analysis of the CAVEOLIN-1 gene at human chromosome 7q31.1 in primary tumours and tumour-derived cell lines. Oncogene, 18, 1881-90.
26. Jenkins RB, Qian J, Lee HK, et al (1998). A molecular cytogenetic analysis of 7q31 in prostate cancer. Cancer Res, 58, 759-66.
27. Jones C, Mackay A, Grigoriadis A, et al (2004). Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. Cancer Res, 64, 3037-45.
28. Kaaks R, Rinaldi S, Key TJ, et al (2005). Postmenopausal serum androgens, oestrogens and breast cancer risk: the european prospective investigation into cancerand nutrition. Endocr Relat Cancer, 12, 1071-82.
29. Koleske AJ, Baltimore D, Lisanti MP (1995). Reduction of caveolin and caveolae in oncogenically transformed cells. Proc Natl Acad Sci USA, 92, 1381-5.
30. Lee H, Park DS, Razani B, et al (2002). Caveolin-1mutations (P132L and null) and the pathogenesis of breast cancer: caveolin-1 (P132L) behaves in a dominant-negative manner and caveolin-1 null mice show mammary epithelial cell hyperplasia. Am J Pathol, 161, 1357-69.
31. Lee SW, Reimer CL, Oh P, et al (1998). Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene, 16, 1391-7.
32. Li S, Okamoto T, Chun M, et al (1995). Evidence for a regulated interaction between heterotrimeric G proteins and caveolin. J Biol Chemm, 270, 15693-701.
33. Macleod KF, Jacks T (1999). Insights into cancer from transgenic mouse models. J Pathol, 187, 43-60.
34. Nishizuka S, Tamura G, Terashima M, et al (1997).Commonly deleted region on the long armof chromosome 7 in differentiated adenocarcinoma of the stomach. Br J Cancer, 76, 1567-71.
35. Park DS, Razani B, Lasorella A, et al (2001). Evidence that Myc isoforms transcriptionally repress caveolin-1 gene expression via an INR-dependent mechanism. Biochemistry, 40, 3354-62.
36. Park SS, Kim JE, Kim YA, et al (2005). Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast. Histopathology, 47, 625-30.
37. Parkin DM, Bray F, Ferlay J, et al (2005). Global cancer statistics, 2002. CA Cancer J Clin, 55, 74-108.
38. Pflug BR, Reiter RE, Nelson JB (1999). Caveolin expression is decreased following androgen deprivation in human prostate cancer cell lines. Prostate, 40, 269-73.
39. Pinilla SM, Honrado E, Hardisson D, et al (2006). Caveolin-1expression is associated with a basal-like phenotype in sporadica nd hereditary breast cancer. Breast Cancer ResTreat, 99, 85-90.
40. Racine C, Belanger M, Hirabayashi H, et al (1999). Reduction of caveolin 1 gene expression in lung carcinoma cell lines. Biochem Biophys Res Commun, 255, 580-6.
41. Razani B, Lisanti MP (2001). Caveolin-deficient mice: insights into caveolar function human disease. J Clin Invest, 108, 1553-61.
42. Razani B, Zhang XL, Bitzer M, et al (2001). Caveolin-1 regulates transforming growth factor (TGF)-beta/SMAD signaling through an interaction with the TGF-beta type I receptor. J Biol Chem, 276, 6727-38.
43. Razani B, Altschuler Y, Zhu L, et al (2000). Caveolin-1 expression is down-regulated in cells transformed by the human papilloma virus in a p53-dependent manner. Replacement of caveolin-1 expression suppresses HPV-mediated cell transformation. Biochemistry, 39, 13916-24.
44. Rothberg KG, Heuser JE, Donzell WC, et al (1992). Caveolin, a protein component of caveolae membrane coats. Cell, 68, 673-82.
45. Sagara Y, Mimori K, Yoshinaga K, et al (2004). Clinical significance of caveolin-1, caveolin-2, and HER2/neu mRNA expression inhuman breast cancer. Br J Cancer, 91, 959-65.
46. Scherer PE, Okamoto T, Chun M, et al (1996). Identification, sequence and expression of caveolin-2 defines a caveolin gene family. Proc Natl Acad Sci U S A, 93, 131-5.
47. Shridhar V, Sun QC, Miller OJ, et al (1998). Loss of heterozygosity on the long arm of human chromosome 7 in sporadic renal cell carcinomas. Oncogene, 15, 2727-33.
48. Simpson HW, Candlish W, Pauson AW, et al (1998). Cancer is in the premenopause. Lancet, 332, 74-6.
49. Sipetić S, Petrović V, Milić Z, et al (2004). Breast cancer incidence among women of Branicevo region in the period 1991-2000. Med Pregl, 57, 467-72.
50. Van den Eynden GG, Van Laere SJ, Van derAuwera I, et al (2006). Overexpression of caveolin-1and -2 in cell lines and in human samples of inflammatory breast cancer. Breast Cancer ResTreat, 95, 219-28.
51. Williams TM, Lisanti MP (2005). Caveolin-1 in oncogenic transformation, cancer, and metastasis. Am J Physiol Cell Physiol, 288, C494-506.
52. Xie GS, Hou AR, Li LY, et al (2006). Aberrant p16 promoter hypermethylation in bronchial mucosae as a biomarker for the early detection of lung cancer. Chin Med J, 119, 1469-72.
53. Yang G, Truong LD, Timme TL, et al (1998). Elevated expression of caveolin is associated with prostate and breast cancer. Clin Cancer Res, 4, 1873-80.
54. Zenklusen JC, Conti CJ, Green ED (2001). Mutational and functional analyses reveal that ST7 is a highly conserved tumor-suppressor gene on human chromosome 7q31. Nat Genet, 27, 392-8.
55. Zou W, McDaneld L, Smith LM (2003). Caveolin-1 haploin sufficiency leads to partial transformation of human breast epithelial cells. Anticancer Res, 23, 4581-6.